(Sharecast News) - Shield Therapeutics said on Thursday that the US Food and Drug Administration (FDA) has granted priority review to extend the indication of its oral iron therapy Accrufer/Feraccru to adolescents aged 10 and above, with potential approval expected in 2026.
The AIM-traded firm said the application followed positive results...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE